DJ FDA To Issue Guidance For Vaccine Developers About New Variants -- MarketWatch
The U.S. government plans to provide additional guidance about new strains of SARS-CoV-2 to companies that have developed or are developing new tests, treatments, and vaccines. The Food and Drug Administration said Thursday it's already discussing with companies how the new variants may affect the efficacy of their products. This includes makers of monocolonol antibodies, which are thought to be negatively affected (http://www.marketwatch.com/story/drugmakers-examine-effectiveness-of-covid-19-vaccines-and-treatments-against-new-more-infectious-south-african-strain-11611869110) by B.1.351, a more infectious strain that emerged from South Africa. Eli Lilly & Co. (LLY) and Regeneron Pharmaceuticals Inc. (REGN) both have authorized COVID-19 antibody treatments. The regulator also said it believes that currently available vaccines still prevent infections with the virus and that most currently available tests are also still effective at detecting the coronavirus. It previously said that three tests may be impacte (http://www.marketwatch.com/story/fda-identifies-3-covid-19-tests-that-may-be-impacted-by-new-variant-2021-01-08)d by new variants. "We do not believe there will be the need to start at square one with any of these products," the FDA said. "We recognize we are in a pandemic."
(END) Dow Jones Newswires
February 05, 2021 11:05 ET (16:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.